Conte PF - Search Results

1

High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).

Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, Cure JH, Orlandini C, Ferrante P, Conte PF, Demirer T; EBMT Solid Tumor Working Party. Bengala C, et al. Among authors: conte pf. Bone Marrow Transplant. 2005 Jul;36(1):25-31. doi: 10.1038/sj.bmt.1705007. Bone Marrow Transplant. 2005. PMID: 15908977

2

Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.

Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, Rosso R, Conte PF. Chiara S, et al. Among authors: conte pf. Eur J Cancer. 1995;31A(3):296-301. doi: 10.1016/0959-8049(94)00487-p. Eur J Cancer. 1995. PMID: 7786592 Clinical Trial.

3

Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma.

Conte PF. Conte PF. Bull Cancer. 1993 Feb;80(2):152-5. Bull Cancer. 1993. PMID: 8173167

4

The impact of received dose intensity on the outcome of advanced ovarian cancer.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al. Repetto L, et al. Among authors: conte pf. Eur J Cancer. 1993;29A(2):181-4. doi: 10.1016/0959-8049(93)90169-g. Eur J Cancer. 1993. PMID: 8422279 Clinical Trial.

5

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.

Bengala C, Pazzagli I, Tibaldi C, Favre C, Vanacore R, Greco F, Mazzoni A, Menconi MC, Macchia P, Conte PF. Bengala C, et al. Among authors: conte pf. Cancer. 1998 Mar 1;82(5):867-73. Cancer. 1998. PMID: 9486575 Clinical Trial.

6

Paclitaxel plus epirubicin in advanced breast cancer.

Conte PF, Gennari A, Salvadori B, Pazzagli C, Bengala C. Conte PF, et al. Oncology (Williston Park). 1998 Jan;12(1 Suppl 1):40-4. Oncology (Williston Park). 1998. PMID: 9516603 Free article. Clinical Trial.

7

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.

Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF. Gennari A, et al. Among authors: conte pf. J Clin Oncol. 1999 Nov;17(11):3596-602. doi: 10.1200/JCO.1999.17.11.3596. J Clin Oncol. 1999. PMID: 10550159 Clinical Trial.

8

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.

Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Algeri R, Bonifazi V, Fioretto ML, Orlandini C, Conte PF. Ricci S, et al. Among authors: conte pf. Lung Cancer. 2000 Feb;27(2):75-80. doi: 10.1016/s0169-5002(99)00098-7. Lung Cancer. 2000. PMID: 10688490 Clinical Trial.

9

The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.

Gennari A, Donati S, Danesi R, Fogli S, Orlandini C, Del Tacca M, Conte PF. Gennari A, et al. Among authors: conte pf. Semin Oncol. 2000 Feb;27(1 Suppl 2):14-9. Semin Oncol. 2000. PMID: 10697031 Clinical Trial.

10

Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.

Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF. Ricci S, et al. Among authors: conte pf. Am J Clin Oncol. 2000 Aug;23(4):412-5. doi: 10.1097/00000421-200008000-00020. Am J Clin Oncol. 2000. PMID: 10955874 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

473 results

Search Page